Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FRAMINGHAM, MA / ACCESSWIRE / September 8, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the virtual H.C.

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Kadmon Hlds

Safe Bulkers

Senseonics Holdings

Verb Technology Company Inc

Penny stocks to buy according to analysts with price targets up to 300% right now. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 300% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks Analysts Say To Buy With Targets Up To 300%

Continued execution on XCART TM pre-clinical development plan and progress toward IND-enabling studies  Strong royalty growth with PolyXen® platform technology  Bolstered cash position with recently completed $12.5 million private placement  FRAMINGHAM, MA / ACCESSWIRE / August 13, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the second quarter of 2021 and provided a corporate update. "Over the course of the second quarter, we continued to execute our innovative and differentiated XCART program, and the technical progress we've accomplished brings us closer to the critical milestone of conducting IND-enabling studies in the United States.

Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

The shares of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by over 37% during intraday trading. This is why it happened.

Xenetic Biosciences Shares Increase Over 37% Intraday: Why It Happened

The stock price of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by 65.11% yesterday. This is why it happened.

XBIO Stock Increased 65.11%: Details You Should Know

FRAMINGHAM, MA / ACCESSWIRE / July 28, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced the closing of its previously announced private placement with a single healthcare-focused institutional investor for 4,629,630 shares of its common stock (or common stock equivalents) at a purchase price per share of $2.70, priced at-the-market under Nasdaq rules. The gross proceeds to Xenetic totaled approximately $12.5 million before deducting placement agent fees and other offering expenses.

Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market

XBIO stock is continuing a heck of a week. Just days after it was boosted by Takeda's expansion news, it's looking at a big private sale.

XBIO Stock: Xenetic Soars on Private Placement Announcement

AzurRx BioPharma

Chembio Diagnostics

Why investors are watching these 3 biotech penny stocks right now The post Biotech Penny Stocks Are Heating Up, Here's 3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Penny Stocks Are Heating Up, Here's 3 To Watch Right Now

The stock price of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by over 30% pre-market. This is why it happened.

XBIO Stock Increases Over 30% Pre-Market: Why It Happened

FRAMINGHAM, MA / ACCESSWIRE / July 26, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase of 4,629,630 shares of its common stock (or common stock equivalents) at a purchase price per share of $2.70, in a private placement priced at-the-market under Nasdaq rules. Additionally, Xenetic has also agreed to issue to the investor warrants to purchase up to 4,629,630 shares of common stock.

Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market

XBIO stock is racing to the moon today, as Takeda Pharmaceuticals makes an announcement that will see higher demand for Xenetic products. The post XBIO Stock: Xenetic Soars on Takeda Expansion News appeared first on InvestorPlace.

XBIO Stock: Xenetic Soars on Takeda Expansion News

Medigus Ltd Sponsored

Moving Image Technologies

These penny stocks shot up substantially today; worth it or not? The post 3 Penny Stocks That Exploded Today, One Up 144% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That Exploded Today, One Up 144%

The stock price of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by over 15% pre-market. This is why it happened.

XBIO Stock Increases Over 15% Pre-Market: Why It Happened

The stock price of Xenetic Biosciences Inc (NASDAQ: XBIO) increased 27.96% after hours. Why It Happened The post XBIO Stock Increased 27.96% After Hours: Why It Happened appeared first on Pulse 2.0.

XBIO Stock Increased 27.96% After Hours: Why It Happened

The stock price of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by over 59% during intraday trading. These are some details you should know.

XBIO Stock Increases Over 59% Intraday: Details

Allied Healthcare Products

Star Equity Holdings

Are these volatile penny stocks worth watching after big gains today? The post 3 Penny Stocks to Watch Making Big Gains Today, One Up 130% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch Making Big Gains Today, One Up 130%

The stock price of Xenetic Biosciences Inc (NASDAQ: XBIO) increased by over 20% pre-market. These are the details.

XBIO Stock Price: Over 20% Increase Pre-Market Details

Continued Execution on Xcart™ Development Plan With Commencement of Exploratory Patient Biopsy Trial Expected To Position the Company To Conduct Ind-Enabling Studies in the United States Licensing Partners Leveraging PolyXen® Platform Technology Continue To Make Clinical, Regulatory and Commercial Advancement FRAMINGHAM, MA / ACCESSWIRE /  May 12, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the first quarter of 2021 and provided a corporate update. "During the first quarter our focus remained on advancing the development of our XCART™ platform, which we believe has the potential to provide a personalized CAR T therapy targeting cancers with a patient-and tumor-specific approach.

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results

Live video webcast with CEO, Jeffrey Eisenberg on Tuesday, May 18, 2021 at 3:30 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 10, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present the Q2 Virtual Investor Summit on Tuesday, May 18th at 3:30 PM ET. In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit

The stock price of Xenetic Biosciences, Inc. (NASDAQ:XBIO) increased by over 5% pre-market. This is why it happened.

XBIO Stock Price Increased Over 5% Pre-Market: Why It Happened

- Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma (NHL) towards Investigational New Drug (IND) filing in the United States - Study will evaluate the XCART process of neoantigen identification and generation of tumor-specific CAR T candidates, in a real-world clinical setting FRAMINGHAM, MA / ACCESSWIRE / March 29, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced it has received approval to commence its exploratory patient biopsy study in Eastern Europe evaluating XCART. "The start of this study represents an important step forward in our preclinical development program, and we look forward to evaluating the XCART platform applied to tumor samples from NHL patients currently under evaluation or in treatment at the study site.

Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)

Driving development of XCART™ platform and leveraging academic collaborations through preclinical development Recent clinical, regulatory and commercial advancements from licensing partners leveraging PolyXen® platform technology FRAMINGHAM, MA / ACCESSWIRE / March 17, 2021 /  Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the fourth quarter and full year 2020, and provided a corporate update. "Notwithstanding the challenges presented by the COVID-19 pandemic, 2020 was a year of significant progress for the Company, including the establishment of partnerships and academic collaborations and advancement in our development efforts, in particular with respect to CAR design and model cell line development, as well as the strengthening of our financial position.

Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

FRAMINGHAM, MA / ACCESSWIRE / March 3, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

FRAMINGHAM, MA / ACCESSWIRE / January 14, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at NobleCon17 - Noble Capital Markets' Seventeenth Annual Investor Conference on Tuesday, January 19, 2021 at 9:45 AM ET. A high-definition, video webcast will be available at the time of the Company's presentation to those registered to attend the event.

Xenetic Biosciences, Inc. to Present at NobleCon17

FRAMINGHAM, MA / ACCESSWIRE / January 5, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021.

News for Xenetic Biosciences Stock (XBIO)